Loading...
Market
How much in milestone payments will Jnana Therapeutics achieve by December 31, 2025?
2
Resolution / Starting Odds
None • 25%
Up to $100M • 25%
$100M to $200M • 25%
Over $200M • 25%
Official press release from Otsuka Pharmaceutical or Jnana Therapeutics
Story
Otsuka to Acquire Jnana Therapeutics for $1.1 Billion, $800M Upfront
Aug 1, 2024, 08:45 AM
Japan's Otsuka Pharmaceutical has announced an agreement to acquire U.S.-based Jnana Therapeutics for up to $1.1 billion. The deal includes an upfront payment of $800 million and up to $325 million in milestone payments. Jnana, a Boston-based clinical-stage biotech company, is known for its RAPID platform and the JNT-517 oral investigational drug, which has shown effectiveness for phenylketonuria (PKU) in Phase 1b/2 trials. Upon completion of the acquisition, Jnana will operate as a subsidiary of Otsuka in Boston and continue its research and development efforts, including work on autoimmune diseases. The company is led by CEO and co-founder Joanne Kotz. This acquisition adds to the recent uptick in private biotech mergers and acquisitions.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Yes • 50%
No • 50%
FDA approval of JNT-517 • 25%
Initiation of Phase 3 trials for JNT-517 • 25%
New drug discovery announcement • 25%
Other • 25%
None • 25%
Up to $200 million • 25%
$200 million to $600 million • 25%
Above $600 million • 25%
None • 25%
Up to $100 million • 25%
Up to $200 million • 25%
Up to $400 million • 25%
No milestone payments • 25%
Up to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Milestone 1 • 25%
Milestone 2 • 25%
Milestone 3 • 25%
No milestone achieved • 25%